GlassScriptPhysician profile
Mark S Lindsey
NPI 1225124829
$6,793.00
in general payments reported to CMS, 2019-2025
39 companies · $756 in 2025
The $756 reported for 2025 was more than what 81% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,174 · 2020: $1,220 · 2021: $1,130 · 2022: $623 · 2023: $770 · 2024: $1,121 · 2025: $756.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,622 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $23.63.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,622.43 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $23.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,039.98 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $917.00 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Amgen INC. | $615.88 | 2019-2025 | Repatha, Repatha, Otezla |
| Glaxosmithkline, LLC. | $483.10 | 2020-2024 | Arexvy, Trelegy Ellipta |
| Abbvie INC. | $426.97 | 2019-2025 | |
| Ibsa Pharma INC. | $371.44 | 2019-2024 | Tirosint, Licart, Tirosint |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $355.37 | 2019-2025 | Xifaxan |
| Kowa Pharmaceuticals America, INC. | $354.92 | 2019-2025 | Zoryve |
| Lilly USA, LLC | $321.77 | 2019-2024 | Jardiance, Mounjaro |
| Pfizer INC. | $231.35 | 2019-2024 | |
| Allergan, INC. | $209.82 | 2019-2020 | |
| Amarin Pharma, INC. | $156.68 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $120.95 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $110.36 | 2019-2025 | Trintellix |
| Inspire Medical Systems, INC. | $107.15 | 2023-2024 | Inspire |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Lindsey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.